Giant Roche wades into the preclinical NLRP3 pool, bagging Jecure for their anti-inflammatory team at Genentech
You can now count the biopharma giant Roche among the growing number of players fascinated by the potential of NLRP3 inhibition.
Their big California subsidiary …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
